SAN FRANCISCO, Nov. 14, 2018 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) today announced the appointment of
Wei Lin, M.D., as Senior Vice
President of Clinical Development and Head of Nektar's Oncology
Programs. In this role, Dr. Lin will lead development strategy and
study oversight of the company's immuno-oncology candidates and
other oncology programs.
"Dr. Lin has extensive experience leading global development
teams and conducting clinical research at leading institutions,"
said Mary Tagliaferri, M.D., Senior
Vice President of Clinical Development and Chief Medical Officer at
Nektar Therapeutics. "Dr. Lin's experience in formulating strategy
and designing and monitoring trials will be instrumental as we
continue to advance our immuno-oncology pipeline."
From 2011 to 2018, Dr. Lin was at Genentech, where he served as
the Global Development Leader for cancer immunotherapy in lung and
head and neck cancer, developing strategy, executing
proof-of-concept and registration trials, and gaining approvals of
immunotherapy drugs. During his time at Genentech, he also served
as a core member of the Lung and Head and Neck Cancer Franchise,
identifying opportunities to develop the pipeline and contributing
to decisions in funding and acquisitions/partnering
opportunities.
"I am excited to join Nektar and lead the development strategy
for the company's oncology programs," said Dr. Lin. "These programs
are based on unique mechanisms that target and activate multiple
processes of the immune system. I look forward to contributing to
their continued advancement so we can provide better treatment
options to patients in need."
Prior to joining Genentech, Dr. Lin served as a faculty member
at the M.D. Anderson Cancer Center in Houston in the Department of Thoracic/Head and
Neck Medical Oncology. He received a B.A. from Haverford College and an M.D. from Harvard Medical School. He completed a residency in
internal medicine at Massachusetts General Hospital in Boston and a fellowship in medical oncology at
the University of Texas M.D. Anderson
Cancer Center.
Dr. Lin has extensive clinical research experience and has been
published in more than 15 peer-reviewed journals.
About Nektar Therapeutics
Nektar Therapeutics is
a research-based development stage biopharmaceutical company whose
mission is to discover and develop innovative medicines to address
the unmet medical needs of patients. Our R&D pipeline of new
investigational medicines includes treatments for cancer,
auto-immune disease and chronic pain. We leverage Nektar's
proprietary and proven chemistry platform in the discovery and
design of our new therapeutic candidates. Nektar is headquartered
in San Francisco, California, with additional operations
in Huntsville, Alabama and Hyderabad, India.
Further information about the company and its drug development
programs and capabilities may be found online
at http://www.nektar.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements which can be identified by words such as: "will" and
"can" and similar references to future periods. Examples of
forward-looking statements include, among others, statements we
make regarding the therapeutic potential of our immune-oncology
candidates, and the strategies relating to the development of our
oncology programs. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead,
they are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, anticipated events and trends, and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
to differ materially from those indicated in the forward-looking
statements include, among others: (i) our statements regarding the
therapeutic potential of our pipeline molecules are based on unique
mechanisms that require additional preclinical and clinical
findings and observations to ensure safety and efficacy; (ii) the
clinical and commercial risks associated with our pipeline
molecules remains high and failure can unexpectedly occur at any
stage for one or more of the indications being studied prior to
regulatory approval due to lack of sufficient efficacy, safety
considerations or other factors that impact drug development; (iii)
data reported from ongoing preclinical and clinical trials are
necessarily interim data only and the final results will change
based on continuing observations; (iv) patents may not issue from
our patent applications for our drug candidates, patents that have
issued may not be enforceable, or additional intellectual property
licenses from third parties may be required; and (v) certain other
important risks and uncertainties set forth in Nektar's Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission on November 8, 2018. Any
forward-looking statement made by us in this press release is based
only on information currently available to us and speaks only as of
the date on which it is made. We undertake no obligation to update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
For Investors:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
Jodi Sievers of Nektar Therapeutics
415-482-5593
For Media:
Dan Budwick of 1AB
973-271-6085
dan@1abmedia.com
View original
content:http://www.prnewswire.com/news-releases/nektar-appoints-wei-lin-md-as-senior-vice-president-of-clinical-development-and-head-of-nektars-oncology-programs-300749751.html
SOURCE Nektar Therapeutics